Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Acta Haematol
6 Ann Hematol
1 Biochem Pharmacol
6 Blood
1 Bone Marrow Transplant
1 Cancer
1 Eur J Haematol
4 Int J Hematol
5 J Pediatr Hematol Oncol
1 J Virol
2 Leuk Res
12 Leukemia
1 Oncogene
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. HALAHLEH KA, Ma'koseh M, Sultan I, Rimawi DH, et al
    High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
    Acta Haematol. 2023;146:88-91.

    Ann Hematol

  2. SUN Y, Wang Q, Zhang X, Zhang Z, et al
    Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05106.
    PubMed         Abstract available

  3. ZEIDAN AM, Pollyea DA, Borate U, Vasconcelos A, et al
    Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05109.
    PubMed         Abstract available

  4. DE LA GARZA-SALAZAR F, Gomez-De Leon A, Gomez-Almaguer D, Colunga-Pedraza PR, et al
    Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia.
    Ann Hematol. 2023;102:487-489.

  5. KLEMENT P, Fiedler W, Gabdoulline R, Dallmann LK, et al
    Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
    Ann Hematol. 2023;102:323-328.
    PubMed         Abstract available

  6. KUNDU R, Seeger R, Elfassy MD, Rozenberg D, et al
    The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure.
    Ann Hematol. 2023;102:439-445.
    PubMed         Abstract available

  7. HUANG J, Zhu Y, Li J, Yang G, et al
    The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations.
    Ann Hematol. 2023;102:495-497.

    Biochem Pharmacol

  8. LEE YC, Chiou JT, Chang LS
    AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2023 Jan 28:115442. doi: 10.1016/j.bcp.2023.115442.
    PubMed         Abstract available


  9. EDIRIWICKREMA A, Gentles AJ, Majeti R
    Single-cell genomics in AML: extending the frontiers of AML research.
    Blood. 2023;141:345-355.
    PubMed         Abstract available

  10. STURGESS KHM, Wilson NK, Gottgens B
    Introduction to a review series on single-cell genomics: getting ready for clinical impact in leukemia and myeloid neoplasms.
    Blood. 2023;141:323-325.

  11. ANGENENDT L, Rollig C, Montesinos P, Ravandi F, et al
    Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.
    Blood. 2023;141:433-435.

  12. TAHIR SK, Calvo E, Carnero BA, Yuda J, et al
    Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
    Blood. 2023 Jan 30:blood.2022017333. doi: 10.1182/blood.2022017333.
    PubMed         Abstract available

  13. LOPEZ CK, Mercher T
    ERGonomics for EVI1 acute myeloid leukemia.
    Blood. 2023;141:441-443.

  14. PIQUE-BORRAS MR, Jevtic Z, Otzen Bagger F, Seguin J, et al
    The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.
    Blood. 2023 Feb 3:blood.2022017273. doi: 10.1182/blood.2022017273.
    PubMed         Abstract available

    Bone Marrow Transplant

  15. GIEBEL S, Labopin M, Socie G, Aljurf M, et al
    Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EB
    Bone Marrow Transplant. 2023 Feb 1. doi: 10.1038/s41409-023-01917.
    PubMed         Abstract available


  16. SASAKI K, Ravandi F, Kadia TM, Borthakur G, et al
    Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
    Cancer. 2023 Jan 30. doi: 10.1002/cncr.34609.
    PubMed         Abstract available

    Eur J Haematol

  17. NAMPOOTHIRI RV, Tang K, Schuh A, Lam W, et al
    Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis.
    Eur J Haematol. 2023 Feb 2. doi: 10.1111/ejh.13940.
    PubMed         Abstract available

    Int J Hematol

  18. OBO T, Morita K, Sumida Y, Nakazaki-Watadani K, et al
    Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
    Int J Hematol. 2023 Feb 3. doi: 10.1007/s12185-023-03545.
    PubMed         Abstract available

  19. ZHANG M, Xiao F, Li Y, Chen Z, et al
    The miR-106b-25 cluster mediates drug resistance in myeloid leukaemias by inactivating multiple apoptotic genes.
    Int J Hematol. 2023;117:236-250.
    PubMed         Abstract available

  20. IMAIZUMI Y, Iwanaga M, Nosaka K, Ishitsuka K, et al
    Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.
    Int J Hematol. 2023;117:206-215.
    PubMed         Abstract available

  21. TANIGUCHI S, Utsumi S, Kochi Y, Taya Y, et al
    Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation.
    Int J Hematol. 2023;117:287-292.
    PubMed         Abstract available

    J Pediatr Hematol Oncol

  22. DEMEDIS J, Scarbro S, Suresh K, Maloney K, et al
    Hyperglycemia and Other Glycemic Measures Throughout Therapy for Pediatric Acute Lymphoblastic Leukemia and Lymphoma.
    J Pediatr Hematol Oncol. 2023 Jan 12. doi: 10.1097/MPH.0000000000002619.
    PubMed         Abstract available

  23. MACDONALD P, Cranston A, Virdee M, Farncombe T, et al
    Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes.
    J Pediatr Hematol Oncol. 2022 Dec 13. doi: 10.1097/MPH.0000000000002606.
    PubMed         Abstract available

  24. VILLEGAS-RUIZ V, Medina-Vera I, Arellano-Perdomo P, Castillo-Villanueva A, et al
    Low Expression of BRCA1 as a Potential Relapse Predictor in B-Cell Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2022 Nov 21. doi: 10.1097/MPH.0000000000002595.
    PubMed         Abstract available

  25. CHUA LL, Azanan MS, Oh L, Ariffin H, et al
    Physical Inactivity as an Early Sign of Frailty in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2022 Nov 14. doi: 10.1097/MPH.0000000000002586.
    PubMed         Abstract available

  26. YU N, Ye S, Yang Z, Chen Z, et al
    Disseminated Cunninghamella Elegans Infection Diagnosed by mNGS During Induction Therapy in a Child With Intermediate-risk Acute Lymphoblastic Leukemia: A Case Report and Review of Literature.
    J Pediatr Hematol Oncol. 2022 Oct 24. doi: 10.1097/MPH.0000000000002577.
    PubMed         Abstract available

    J Virol

  27. HOSSAIN MB, Kobayashi T, Makimoto S, Matsuo M, et al
    Clone Dynamics and Its Application for the Diagnosis of Enzootic Bovine Leukosis.
    J Virol. 2023;97:e0154222.
    PubMed         Abstract available

    Leuk Res

  28. PREMNATH N, Chung SS, Weinberg OK, Ikpefan R, et al
    Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
    Leuk Res. 2023;125:107001.
    PubMed         Abstract available

  29. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
    Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2022;125:107004.
    PubMed         Abstract available


  30. OHKI K, Butler ER, Kiyokawa N, Hirabayashi S, et al
    Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.
    Leukemia. 2023;37:212-216.

  31. FENG J, Wang Y, Li B, Yu X, et al
    Loss of bisecting GlcNAcylation on MCAM of bone marrow stoma determined pro-tumoral niche in MDS/AML.
    Leukemia. 2023;37:113-121.
    PubMed         Abstract available

  32. VANGALA DB, Nilius-Eliliwi V, Gerding WM, Schroers R, et al
    Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: "High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of
    Leukemia. 2023;37:248-249.

  33. LOCATELLI F, Zugmaier G, Rizzari C, Morris JD, et al
    Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
    Leukemia. 2023;37:222-225.

  34. LEHRNBECHER T, Groll AH, Cesaro S, Alten J, et al
    Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009.
    Leukemia. 2023;37:72-78.
    PubMed         Abstract available

  35. LIESKE A, Agyeman-Duah E, Selich A, Dorpmund N, et al
    A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML.
    Leukemia. 2023;37:79-90.
    PubMed         Abstract available

  36. FORD AM, Colman S, Greaves M
    Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia.
    Leukemia. 2023;37:47-52.

  37. SEMBILL S, Ampatzidou M, Chaudhury S, Dworzak M, et al
    Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
    Leukemia. 2023 Jan 27. doi: 10.1038/s41375-023-01822.
    PubMed         Abstract available

  38. MORENO RUEDA LY, Bryant D, Tapper WJ, Weston-Bell NJ, et al
    The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia.
    Leukemia. 2023 Jan 28. doi: 10.1038/s41375-023-01823.

  39. RYAN CE, Brander DM, Barr PM, Tyekucheva S, et al
    A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leukemia. 2023 Jan 30. doi: 10.1038/s41375-023-01830.
    PubMed         Abstract available

  40. HOCHHAUS A, Rea D, Boquimpani C, Minami Y, et al
    Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
    Leukemia. 2023 Jan 30. doi: 10.1038/s41375-023-01829.
    PubMed         Abstract available

  41. BOILA LD, Ghosh S, Bandyopadhyay SK, Jin L, et al
    KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
    Leukemia. 2023 Jan 31. doi: 10.1038/s41375-023-01833.
    PubMed         Abstract available


  42. BENCOMO-ALVAREZ AE, Rubio AJ, Olivas IM, Gonzalez MA, et al
    Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
    Oncogene. 2021;40:2697-2710.
    PubMed         Abstract available

    PLoS One

  43. PETERSEN MI, Carignano HA, Mongini C, Gonzalez DD, et al
    Bovine leukemia virus encoded blv-miR-b4-3p microRNA is associated with reduced expression of anti-oncogenic gene in vivo.
    PLoS One. 2023;18:e0281317.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.